AllThingsLifeSciences/CleanTech: 2010

ATLS-CT_Logo_SM

Springboard’s 20th Venture Forum Program

About AllThingsLifeSciences/CleanTech: 2010

The Springboard: AllThingsLIfeSciences/CleanTech: 2010 program featured 20 of the most promising high-growth, women-led companies in t biotech, biopharma, health IT, healthcare, medical devices, and diagnostics. The Forum was held in June, 2010 in Boston, MA showcasing the entrepreneurs before an audience of the area’s top corporate, angel, and venture investors.

About our acceleratorsGet Involved
PDF Fact SheetPDF Event Recap

Event Pictures

Quick Navigation

Supporting Organizations

Forum Committees

Investor Committee

  • Jack Ahrens, TGap Ventures
  • Jahanara Ali, NYC Investment Fund
  • Richard Anders, Mass Medical Angels (MA2)
  • Ben Auspitz, Fidelity Biosciences
  • Elizabeth Bailey, Commons Capital
  • Kevin Bitterman, Polaris Venture Partners
  • Dan Broderick, BioGenerator
  • Mike Bunker, Early Stage Partners
  • James Burgum, Arthur Ventures
  • Christian Cortis, ATV Capital
  • Ann Dewitt, Flagship Ventures
  • Cynthia Doerr, Essex Woodlands Health Ventures
  • Ted Driscoll, Claremont Creek Ventures
  • Suzette Dutch, Triathlon Medical Ventures
  • Stuart Eckmann, Life Science Angels
  • Teresa Esser, Capital Midwest Fund
  • Pete Farner, TGap Ventures
  • Lauren Flanagan, Phenomenelle Angels
  • Nancy Floyd, Nth Power
  • Jennifer Friel Goldstein, Pfizer Inc
  • Andrew Friendly, ATV Capital
  • Jan Garfinkle, Arboretum Ventures
  • Karen Hong, ProQuest Investments
  • Eva Jack, Medimmune Ventures
  • Elaine Jones, Pfizer, Inc.
  • Kef Kasdin, Battelle Ventures
  • Stephen Kraus, Bessemer Venture Partners
  • Ron Lennox, CHL Medical Partners
  • Reid Leonard, Merck & Co, Inc.
  • Debra Liebel, Domain Associates
  • Ellen Lubman, Bristol-Meyers Squibb
  • Michael Lytton, Biogen Idec
  • Carol Marino, Syngenta Venture Capital
  • Michael Melnick, CMEA Capital
  • Dan Meyer, Point Judith Capital
  • Pat Morand, SMLS Venture Fund
  • Todd Morrill, Bio-Rad Laboratories
  • Dana Ono, VIMAC Ventures LLC
  • Catherine Oyler, Johnson & Johnson
  • William Paiva, Sevin Rosen Funds
  • Ann Partlow, Earthrise Capital
  • Pooja Pathak, Oxford Bioscience Partners
  • Susan Rohrer, Merck & Co, Inc.
  • Amita Shukla, New Enterprise Associates
  • Lauren Silverman, Novartis Venture Capital
  • Karen Spilizewski, RiverVest Venture Partners
  • Richard Stuebi, Early Stage Partners
  • Geeta Vemuri, BioVentures
  • Tracy Warren, Battelle Ventures
  • Yael Weiss, Merck & Co, Inc.
  • Alex Zisson, Thomas McNerney & Partners

Alumnae Committee

  • Jahan Ali, NYC Investment Fund
  • Jack Ahrens, TGap Ventures
  • Rajni Aneja, zuChem, Inc.
  • Sylvia Aruffo, Communication Science
  • Carole Bellis, Wilson Sonsini
  • Karen Bixby
  • Rachel Braun Scherl, Semprae Laboratories
  • Manny Cho, Aon
  • Corinne Bright, ONSET Ventures
  • Kirstie Chadwick, Growth Innovators
  • Ellen Corenswet, Covington & Burling LLP
  • Christian Cortis, ATV Capital
  • Jacqueline Crespo, Cassidy & Associates
  • Kathleen DeRose, Golden Seeds
  • Ann Dewitt, Flagship Ventures
  • Mike Diem, SR One
  • Ted Driscoll, Claremont Creek Ventures
  • Teresa Esser, Capital Midwest Fund
  • Bill Fair, Ajax Ventures
  • Joan Fallon, Curemark, LLC
  • Pete Farner, TGap Ventures
  • Lauren Flanagan, Phenomenelle Angels
  • Barbara Fox, Avaxia Biologics
  • Sara Frankel, Consultant
  • Jennifer Friel Goldstein, Pfizer Venture Investments
  • Ann Gaddy, Life Science Angels
  • Gary Gamerman, Seraphim Life Sciences
  • Jan Garfinkle, Arboretum Ventures
  • Annette Gilchrist, Midwestern University
  • Stephanie Grossman, Digital & Media Executive
  • Elma, Hawkins, Biotechnology Consultant
  • Diana Hoffman, Hoffman Management Consulting
  • Karen Hong, ProQuest Investments
  • Mary Howard, Design Technologies, LLC
  • Nigel Howard, Covington & Burling LLP
  • Kef Kasdin, Battelle Ventures
  • Stephen Kraus, Bessemer Venture Partners
  • Reid Leonard, Merck & Co., Inc.
  • Roberta Lee, Manoa Medical, Inc.
  • Donna Lencki, Geneia
  • Ellen Lubman, Bristol-Meyers Squibb
  • Carol Marino, Syngenta Venture Capital
  • Deborah Mash, Ibogen, Inc.
  • Patricia Meisner, AdhereTx Corporation
  • Dan Meyer, Point Judith Capital
  • Jessica Milner, Covington & Burling
  • Arikha Moses, The Vertical Group
  • Catherine Mulligan, William Gallagher Associates
  • Carol Nacy, Sequella, Inc.
  • Mike O’Donnell, Wilson Sonsini
  • Anjali Oberoi, NewSeed Advisors
  • Jill Osur, Blend Tech Solutions
  • Catherine Oyler, Johnson & Johnson
  • Nancy Parenteau, Parenteau BioConsultants, LLC
  • Ann Partlow, Earthrise Capital
  • Amy Ravi, ExtendMed
  • Ingrid Rechtinv, Covington & Burling
  • Karen Spilizewski, RiverVest Venture Partners
  • LeAnne Tourtellotte, Illinois Technology Association
  • Liat Tsoref, Slender Medical Ltd.
  • Mary Wallace Jaensch, Semprae Laboratories
  • Sue Washer, Applied Genetic Technologies
  • Yael Weiss, Merck & Co., Inc.
  • Patti White, Medical Technology
  • Gervaise Wilhelm, Closys Corporation
  • Donna Williams, Ceres Venture Fund
  • Alex Zisson, Thomas, McNerney & Partners
  • Diane Zuckerman, Evidence-Based Solutions

CoachingCommittee

  • Milena Adamian, Easton Capital
  • Jack Ahrens, TGAP Ventures
  • Jahanara Ali, NYC Investment Fund
  • Rajni Aneja, ZuChem
  • Elizabeth Bailey, Commons Capital
  • Leslie Bane, National Semiconductor
  • Susan Berland, Consultant
  • Carlos Berland, Grant Thornton LLP
  • Anne Marie Biernacki, AdhereTx Corporation
  • Kevin Bitterman, Polaris Ventures
  • Rachel Braun Scherl, Semprae Laboratories
  • A.G. Breitenstein, Humedica
  • Corinne Bright, ONSET Ventures
  • Candice Brown Elliot, Nouvoyance Inc.
  • Mike Bunker, Early Stage Partners
  • Kerry Burke, Covington & Burling LLP
  • Chris Byrd, Wilson Sonsini
  • Amanda Cashin, Alexandria Real Estate Equities
  • Maria Casini, Guard Dog Brand Development
  • Vita Cassese, Exigen Capital
  • Maxine Champion
  • Terry Chase Hazell, Texas State University
  • Manny Cho, Aon
  • Amy Chu, Tiger Advisors LLC
  • Martha Connolly, Maryland Technology Enterprise Institute
  • Ellen Corenswet, Covington & Burling LLP
  • Christian Cortis, ATU Capital
  • Suzanne Cross, Johnson & Johnson
  • Cynthia Curtis, CA Technologies
  • Bruce Deming, Covington & Burling LLP
  • Camille DeSantis, Guard Dog Brand Development
  • Ann Dewitt, Flagship Ventures
  • Brendan Doherty, CA Technologies
  • Ted Driscoll, LSA Member, Claremont Creek
  • Suzette Dutch, Triathlon Medical Ventures
  • Teresa Esser, Capital Midwest Fund II
  • Lauren Flanagan, Phenomenelle Angels
  • Carmen Fonda, Venable LLP
  • Barbara Fox, Avaxia Biologics
  • Jennifer Friel Goldstein, Pfizer Venture Investments
  • Andrew Friendly, ATV Capital
  • Oren Fuerst, Tevel Angels
  • Angela Garcia-Lopez, Grant Thornton LLP
  • Megan Gates, Mintz Levin
  • Judy Giordon, NCIIA
  • Julie Goonewardene, Purdue Research Foundation
  • Robert Gottlieb, RMG Associates LLC
  • Karin Gregory, Furman Gregory Deptula
  • Colleen Grimm, William Gallagher Associates
  • Liz Groover
  • David Guin, Withers Bergman
  • Cal Hackeman, Grant Thornton LLP
  • Jessica Hall Harrington, Broadview Ventures
  • Elma Hawkins, Consultant
  • Sarah Hoagland, Covington & Burling LLP
  • Diana Hoffman
  • Karen Hong, ProQuest Investments
  • Mary Howard, Design Technologies LLC
  • Nigel Howard, Covington & Burling LLP
  • Dave Hsu, Consultant
  • Eva Jack, MedImmune Ventures
  • Sven Jacobson, Carrot Capital
  • Christine Janis, Grant Thornton LLP
  • Elaine Jones, Pfizer Inc.
  • Veronica Jordon
  • Tanya Kanigan
  • Kef Kasdin, Battelle Ventures
  • Dr. Hollis Kleinert, KSC Life Science Advisors
  • Stephan Kraus, Bessemer Venture Partners
  • Roberta Lee, Manoa Medical
  • Donna Lencki, Geneia
  • Ron Lennox, CHL Medical Partners
  • Emily Leonard, Covington & Burling LLP
  • Reid Leonard, Merck & Co., Inc.
  • Scott Levy, Grant Thornton LLP
  • Emily Levy, Synergy Partners
  • David Lewandoski, Grant Thornton
  • Debra Liebert, Domain Associates
  • Ellen Lubman, Bristol-Meyers Squibb
  • Joan Lyman
  • Michael Lytton, Biogen Idec
  • Rob Mashal, Alinea Pharmaceuticals
  • Andrea McCormick
  • Chris Meda, Arxis Biotechnologies
  • Kevin Mendelsohn, Jumpstart, Inc.
  • Dan Meyer
  • Jessica Milner, Covington & Burling LLP
  • Pat Morand, Southwest Michigan First
  • Todd Morrill, Bio-Rad Laboratories
  • Toby Moskovits, Heritage Equity Partners
  • Catherine Mulligan
  • Michael Murdoch, Aon
  • Nalini Murdter
  • Carol Nichols, vcfo
  • Dana Ono, VIMAC Ventures LLC
  • Jill Osur, Blend Tech Solutions
  • Cat Oyler, Johnson & Johnson
  • William Paiva, Seven Rosin Funds
  • Ann Partlow, Earthrise Capital
  • John Perchorowicz, Triage Masters LLC
  • Amy Ravi, Extend Med
  • Lisa Richardson
  • Carey Roberts, Covington & Burling LLP
  • Paul Rogers, Covington & Burling LLP
  • Susan Rohrer, Merck & Co., Inc.
  • Lisa Russell, Grant Thornton
  • Mira Sahney
  • Ginette Serrero, A & G Pharmaceutical
  • Christy Shaffer, Inspipre Pharmaceuticals
  • Stefanie Shelley
  • Emily Sheridan, Alexandria Real Estate Equities
  • Scarlet Shore, Alexandria Real Estate Equities
  • Lauren Silverman, Novartis Venture Capital
  • JC Simabana, SVB Capital
  • Brenda Simensky, Withers Bergman
  • Karen Spilizewski, RiverVest Venture Partners
  • Richard Stuebi, Early Stage Partners
  • Alison Taunton Rigby, RiboNovix Inc.
  • Lee Tiedrich, Covington & Burling, LLP
  • Alison Tjosvold, Grant Thornton LLP
  • Amy Toro, Covington & Burling LLP
  • Effie Toshav, Wilson Sonsini
  • Alexis Traynor Kaplan
  • Liat Tsoref, Slender Medical
  • Misti Ushio, Harris & Harris Group Inc
  • Geeta Vemuri, Quaker BioVentures
  • Becky Voorheis
  • Catherine Vorwald, Wexford Science & Technology
  • Joan Vrtis, Kemeta
  • Mary Wallace Jaensch, Semprae Laboratories
  • Yael Weiss, Merck & Co Inc
  • Patti White
  • Amy Wildstein, Boldcap Ventures
  • Donna Williamson, Ceres Venture Fund
  • Jeff Wu, Covington & Burling LLP
  • Alex Zisson, Thomas McNerny & Partners
  • Diane Zuckerman, Evidence-Based Solutions